Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

Keiko Azuma,1 Ryo Asaoka,1 Aya Matsuda,2 Jihee Lee,3 Kimiko Shimizu,1 Hiroko Inui,1 Hiroshi Murata,1 Asako Ogawa,1 Motoshi Yamamoto,1 Tatsuya Inoue,1 Ryo Obata1 1Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan; 2Department of O...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Azuma K, Asaoka R, Matsuda A, Lee J, Shimizu K, Inui H, Murata H, Ogawa A, Yamamoto Motoshi, Inoue T, Obata R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	typical neovascular age-related macular degeneration polypoidal choroidal vasculopathy persistent exudative changes with ranibizumab aflibercept two-year outcome Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0ed56811b4514a08bee6db7ae667e10e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ed56811b4514a08bee6db7ae667e10e
record_format	dspace
spelling	oai:doaj.org-article:0ed56811b4514a08bee6db7ae667e10e2021-12-02T01:48:37ZTwo-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients1177-5483https://doaj.org/article/0ed56811b4514a08bee6db7ae667e10e2018-08-01T00:00:00Zhttps://www.dovepress.com/two-year-outcome-of-treat-and-extend-aflibercept-after-ranibizumab-in--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Keiko Azuma,1 Ryo Asaoka,1 Aya Matsuda,2 Jihee Lee,3 Kimiko Shimizu,1 Hiroko Inui,1 Hiroshi Murata,1 Asako Ogawa,1 Motoshi Yamamoto,1 Tatsuya Inoue,1 Ryo Obata1 1Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan; 2Department of Ophthalmology, Toranomon Byoin, Tokyo, Japan; 3Department of Ophthalmology, Miyata Eye Hospital, Miyakonojo, Japan Background: The purpose of the study was to evaluate the 2-year outcome and predictive factors of treat-and-extend aflibercept in patients with eyes affected by typical neovascular age-related macula degenelation (t-AMD) or polypoidal choroidal vasculopathy (PCV), who were switched from ranibizumab. Patients and methods: The patients underwent three monthly aflibercept injections and subsequent administration following the treat-and-extend protocol. Sixty-two eyes of 62 patients were reviewed retrospectively. R statistical software was used for statistical analysis. Results: Twenty-two eyes were t-AMD and the remaining 40 eyes were PCV. There was no significant difference in the logarithm of the minimal angle of resolution visual acuity (VA) between baseline and 2 years after switching to aflibercept (0.40 vs 0.40; P=0.99). Multivariate analyses suggested that the following factors were significantly correlated with better VA at 2 years after switching to aflibercept: patients with PCV, the absence of intraretinal fluid at baseline, and better VA at baseline. Conclusion: In conclusion, VA was maintained and there was an anatomical improvement at 2 years in patients with t-AMD and PCV who were switched from ranibizumab to treat-and-extend aflibercept. PCV patients showed more favorable visual outcomes and less injections at 2 years compared to t-AMD patients. Intraretinal fluid and VA at baseline were predictors of VA at 2 years. Keywords: typical neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, persistent exudative changes with ranibizumab, aflibercept, 2-year outcomeAzuma KAsaoka RMatsuda ALee JShimizu KInui HMurata HOgawa AYamamoto MotoshiInoue TObata RDove Medical Pressarticletypical neovascular age-related macular degenerationpolypoidal choroidal vasculopathypersistent exudative changes with ranibizumabaflibercepttwo-year outcomeOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1589-1597 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	typical neovascular age-related macular degeneration polypoidal choroidal vasculopathy persistent exudative changes with ranibizumab aflibercept two-year outcome Ophthalmology RE1-994
spellingShingle	typical neovascular age-related macular degeneration polypoidal choroidal vasculopathy persistent exudative changes with ranibizumab aflibercept two-year outcome Ophthalmology RE1-994 Azuma K Asaoka R Matsuda A Lee J Shimizu K Inui H Murata H Ogawa A Yamamoto Motoshi Inoue T Obata R Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
description	Keiko Azuma,1 Ryo Asaoka,1 Aya Matsuda,2 Jihee Lee,3 Kimiko Shimizu,1 Hiroko Inui,1 Hiroshi Murata,1 Asako Ogawa,1 Motoshi Yamamoto,1 Tatsuya Inoue,1 Ryo Obata1 1Department of Ophthalmology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan; 2Department of Ophthalmology, Toranomon Byoin, Tokyo, Japan; 3Department of Ophthalmology, Miyata Eye Hospital, Miyakonojo, Japan Background: The purpose of the study was to evaluate the 2-year outcome and predictive factors of treat-and-extend aflibercept in patients with eyes affected by typical neovascular age-related macula degenelation (t-AMD) or polypoidal choroidal vasculopathy (PCV), who were switched from ranibizumab. Patients and methods: The patients underwent three monthly aflibercept injections and subsequent administration following the treat-and-extend protocol. Sixty-two eyes of 62 patients were reviewed retrospectively. R statistical software was used for statistical analysis. Results: Twenty-two eyes were t-AMD and the remaining 40 eyes were PCV. There was no significant difference in the logarithm of the minimal angle of resolution visual acuity (VA) between baseline and 2 years after switching to aflibercept (0.40 vs 0.40; P=0.99). Multivariate analyses suggested that the following factors were significantly correlated with better VA at 2 years after switching to aflibercept: patients with PCV, the absence of intraretinal fluid at baseline, and better VA at baseline. Conclusion: In conclusion, VA was maintained and there was an anatomical improvement at 2 years in patients with t-AMD and PCV who were switched from ranibizumab to treat-and-extend aflibercept. PCV patients showed more favorable visual outcomes and less injections at 2 years compared to t-AMD patients. Intraretinal fluid and VA at baseline were predictors of VA at 2 years. Keywords: typical neovascular age-related macular degeneration, polypoidal choroidal vasculopathy, persistent exudative changes with ranibizumab, aflibercept, 2-year outcome
format	article
author	Azuma K Asaoka R Matsuda A Lee J Shimizu K Inui H Murata H Ogawa A Yamamoto Motoshi Inoue T Obata R
author_facet	Azuma K Asaoka R Matsuda A Lee J Shimizu K Inui H Murata H Ogawa A Yamamoto Motoshi Inoue T Obata R
author_sort	Azuma K
title	Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
title_short	Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
title_full	Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
title_fullStr	Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
title_full_unstemmed	Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
title_sort	two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/0ed56811b4514a08bee6db7ae667e10e
work_keys_str_mv	AT azumak twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT asaokar twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT matsudaa twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT leej twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT shimizuk twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT inuih twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT muratah twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT ogawaa twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT yamamotomotoshi twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT inouet twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients AT obatar twoyearoutcomeoftreatandextendafliberceptafterranibizumabinagerelatedmaculardegenerationandpolypoidalchoroidalvasculopathypatients
_version_	1718402881226276864

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

Ejemplares similares